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Abstract
Background: Clozapine, an atypical antipsychotic medication, has been effectively used to treat refractory
schizophrenia. However, the clinical usage of clozapine is limited due to a high incidence of neutropenia or
agranulocytosis. We previously reported that clozapine protected dopaminergic neurons through inhibition of
microglial activation. The purpose of this study was to explore the neuroprotective effects of clozapine metabolites
clozapine N-oxide (CNO) and N-desmethylclozapine (NDC), as well as their propensity to cause neutropenia.
Methods: The primary midbrain neuron-glia culture was applied to detect the neuroprotective and
anti-inflammatory effect of clozapine and its metabolites in lipopolysaccharide (LPS) and MPP+-induced toxicity.
And the subsequent mechanism was demonstrated by gp91phox mutant cell cultures as well as microgliosis cell
lines. In vivo, to confirm the neuroprotective effect of clozapine and CNO, we measured the dopaminergic neuronal
loss and rotarod motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-generated mouse Parkinson’s
disease (PD) model. The neutropenia or agranulocytosis of clozapine and its metabolites was illustrated by white
blood cell count of the treated mice.
Results: We found that, in midbrain neuron-glia cultures, CNO and NDC were more potent than clozapine in
protecting dopaminergic neurons against LPS and MPP+-induced toxicity. CNO and NDC-afforded neuroprotection
was linked to inhibition of microglia-mediated neuroinflammation, as demonstrated by abolished neuroprotection
in microglia-depleted cultures and their capacity of inhibiting LPS-induced release of proinflammatory factors from
activated microglia. NADPH oxidase (NOX2) was subsequently recognized as the main target of CNO and NDC
since genetic ablation of gp91phox, the catalytic subunit of NOX2, abolished their neuroprotective effects. CNO and
NDC inhibited NOX2 activation through interfering with the membrane translocation of the NOX2 cytosolic subunit,
p47phox. The neuroprotective effects of CNO were further verified in vivo as shown by attenuation of dopaminergic
neurodegeneration, motor deficits, and reactive microgliosis in MPTP-generated mouse PD model. More
importantly, unlike clozapine, CNO did not lower the white blood cell count.
Conclusions: Altogether, our results show that clozapine metabolites elicited neuroprotection through inactivation
of microglia by inhibiting NOX2. The robust neuroprotective effects and lack of neutropenia suggest that clozapine
metabolites may be promising candidates for potential therapy for neurodegenerative diseases.
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Background
Clozapine, an atypical antipsychotic medication, is widely
used for treatment-resistant schizophrenia patients, dem-
onstrating greater efficacy against both positive and nega-
tive symptoms, compared with typical antipsychotics [1].
Other benefits of clozapine application include the lack of
extrapyramidal adverse effects [2] and the ability to im-
prove cognitive function [3]. Despite these advantages, the
usage of clozapine is rather restricted due to a relatively
high risk of neutropenia or agranulocytosis [4–6]. Cur-
rently, the mechanism responsible for neutrophil toxicity
of clozapine is not fully understood. N-Desmethylcloza-
pine (NDC) and clozapine N-oxide (CNO), as well as re-
active nitrenium intermediate, are the known major
metabolites of clozapine in humans [7, 8]. In vitro studies
demonstrated that reactive nitrenium intermediates but
not clozapine itself or NDC/CNO is toxic to neutrophils
[9, 10]. In addition, it is generally accepted that NDC and
CNO are different in terms of receptor activity as CNO
has been proved to be pharmacologically inert [11, 12] to
the receptors for which clozapine and NDC function as
agonists or antagonists [11, 13, 14].
Microglia, the resident innate immune cells in the
central nervous system (CNS), serve immune surveil-
lance function in physiological conditions. In response
to certain cues, such as brain injury or immunological
stimuli, microglia are readily activated and play a central
role in the process called “neuroinflammation.” It is now
widely accepted that dysregulated neuroinflammation
featured by microglial over-activation has significant
impacts on the pathogenesis of neurodegenerative disor-
ders such as Parkinson’s disease (PD) [15, 16] and
Alzheimer’s disease (AD) [17–21]. Furthermore, increas-
ing evidence also suggests an association of neuroinflam-
mation with several psychiatric disorders, including
schizophrenia (SCZ), autism, depression, and anxiety
disorders [22–24].
We have previously reported that clozapine protects
dopaminergic neurons from inflammation-induced dam-
age by inhibiting microglial NADPH oxidase (NOX2, a
superoxide-producing enzyme) in primary cell cultures
[25]. The main purpose of this study was to deter-
mine whether the two different metabolites could be
less toxic than clozapine and preserve the same neu-
roprotective and anti-inflammatory effects of the par-
ent drug. In this study, we found that both CNO
and NDC protected DA neurons through suppres-
sion of microglia-mediated neuroinflammation both
in vitro and in vivo, where inactivation of microglial
NOX2 played a central role. More importantly, un-
like clozapine, CNO displayed no effects on blood
neutrophils. These effects revealed a novel bioactivity




Time-pregnant Fisher F344 rats were provided by the
Charles River Laboratories (Raleigh, NC). Wild-type
C57BL/6J (gp91phox+/+) and phagocytic NADPH oxidase
(NOX2)-deficient (gp91phox−/−) mice were obtained from
the Jackson Laboratory (Bar Harbor, ME). Breeding of
time-pregnant mice was performed with accuracy of
0.5 day. All the mice were euthanized at the desired time
points. Housing, breeding, and experimental use of the
animals were performed in strict accordance with the
National Institutes of Health guidelines. All procedures




dropyridine (MPTP), MPP+, and Leu methyl ester (LME)
were purchased from Sigma-Aldrich (St. Louis, MO).
Clozapine and clozapine N-oxide were obtained from the
NIMH Chemical Synthesis and Drug Supply Program
(Research Triangle Institute, RTP NC). Lipopolysaccharide
(LPS strain O111:B4) was purchased from Calbiochem
(San Diego, CA). WST-1 was purchased from Dojindo
Laboratories (Gaithersburg, MD). Cell culture ingredients
were obtained from Invitrogen (Carlsbad, CA). [3H]DA
was purchased from PerkinElmer Life Sciences (Boston,
MA). The polyclonal anti-tyrosine hydroxylase (TH)
antibody was purchased from CHEMICON International
(Temecula, CA). The polyclonal ionized calcium-binding
adaptor molecule 1 (Iba-1) antibody was purchased from
Wako Chemicals USA (Richmond, VA). The monoclonal
CD11b antibody was purchased from AbDSerotec
(Raleigh, NC). The biotinylated secondary antibodies were
purchased from Vector Laboratories (Burlingame, CA).
Animal treatment
Eight-week-old male C57BL/6J mice received daily
MPTP injections (20 mg/kg, s.c.) for six consecutive
days. One day prior to MPTP injection, clozapine or
CNO (1 mg/kg, s.c.) was administered twice daily for 21
consecutive days. Eight days after initial MPTP injection,
five mice from each group were sacrificed for the detec-
tion of microglial activation in substantia nigra (SN).
Fourteen days after initial MPTP injection, the protect-
ive effects of clozapine and CNO against MPTP-induced
motor deficits were measured by the accelerating rotarod
test. At 8 and 21 days after the first injection of MPTP,
respectively, mice were euthanized, and brains were re-
moved and postfixed in 4 % paraformaldehyde overnight
at 4 °C. Brains were then placed into 30 % sucrose/PBS
solution at 4 °C until the brains sank to the bottom of the
container. Coronal sections including SN pars compacta
(SNpc) were cut on a −20 °C frozen sliding microtome
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(Thermo Scientific, microm HM525) into 40-μm trans-
verse free-floating sections.
Blood analysis
Twenty-one days after the first injection of MPTP, the
mice were euthanized and eyeball blood was collected in a
1.5-ml heparin tube. After a fully vortex, the number of
different types of cells in the blood was counted by an
Automatic Blood cell Counter (Model: CA-800, SANKYO
Inc.).
Rotarod test
The rotarod behavior was measured as described previ-
ously using a Rota-Rod (ZS-RDM R03-1, Zhong-Shi Inc.,
Beijing, China). The parameters of the rotarod system
were set as accelerating speed from 4 to 40 rpm in 300 s
[26, 27]. Mice received three consecutive trials. The rest
period between each trial was 30 min. The mean latency
for the last two trails was used for the analysis.
Immunostaining
The free-floating brain sections or fixed cells in 24-well
culture plate were immune-blocked with 4–10 % goat
serum and then incubated with polyclonal rabbit anti-
TH antibody (1:5000 dilution), or Iba-1 antibody (1:5000
dilution), or rat anti-CD11b antibody (1:800 dilution) for
24 h at 4 °C, respectively. Antibody binding was visual-
ized using a Vectastain ABC Kit (Vector Laboratories,
Inc) and diaminobenzidine (or with cobalt) tablet as
substrate.
Images were recorded with a CCD camera and the Meta-
Morph software (Molecular Devices). TH immunostaining-
reactive (THir) neuron or Iba-1ir microglia number were
counted according to published protocol [28] and was
carried out by at least two investigators without knowledge
of the treatment. For immunocytochemistry staining in 24-
well cell culture, three to six wells per treatment condition
were used, and results from three to five independent
experiments were obtained.
Primary cell cultures
Primary neuron-glia cultures were prepared as described
previously [29]. In brief, dissociated cells from the ven-
tral mesencephalon of embryonic day 14 ± 0.5 Fischer
334 rats, gp91phox+/+or gp91phox−/− mice were seeded at
5.5 × 105 cells/well (rat) or 6.5 × 105 cells/well (mice) in
poly-D-lysine-coated 24-well plates, respectively. The
cultures were maintained at 37 °C in the incubator with
5 % CO2 and 95 % air in minimum essential medium.
The cultures were ready for experiments 7 days later,
when the cultures became mature and stable of each cell
component (astrocytes ~50 %, neurons ~40 %, and
microglia ~10 %) as described previously [29, 30].
Microglia-depleted neuron-glia cultures were obtained
by depleting microglia in neuron-glia cultures with
1.5 mM of LME 48 h after seeding (~45 % neurons and
~55 % astrocyte), as described previously [31].
Mixed-glia cultures were prepared from whole brains
of postnatal day 1 rats as reported before [32]. Briefly,
disassociated cells were seeded into 24-well (1 × 105/
well) or 96-well (5 × 104/well) culture plates and main-
tained in 1 ml/well or 0.2 ml/well of Dulbecco’s modified
Eagle’s medium (DMEM)/F-12 medium. The medium
was changed every 3 days. On 11–12 days after plating,
the cultures were mature and stable with different cell
components [29, 30] (astrocytes ~80 %, GFAP immuno-
positive cells; microglia ~20 % OX-42 immunopositive
cells) ready for drug treatment or superoxide assay.
Culture treatment
Rat mesencephalic neuron-glia cultures or microglia-
depleted neuron-glia cultures were maintained in the
maintenance medium (10 % fetal bovine serum, 10 %
horse serum, 0.1 % D-glucose, 1 % none essential AA, Na
pyruvate 1 %, L-glutamine 1 %, Pen/Strep1% in MEM) for
7 days untile the cultures became mature (astrocytes
~50 %, neurons ~40 %, and microglia ~10 %). Then, the
cultures were pretreated with vehicle or indicated concen-
trations of CNO, NDC, or clozapine prepared in the
serum-reduced treatment medium (2 % fetal bovine
serum, 2 % horse serum, Na pyruvate 1 %, L-glutamine
1 %, Pen/Strep1% in MEM) for 30 min before the addition
of LPS (15 ng/ml) or MPTP (0.25 μM), which also
prepared in the serum-reduced treatment medium. At
indicated time points after treatment, the culture super-
natant was collected for the detection of inflammatory
factors. And 7 days after LPS or MPTP treatment, the
protective effects of CNO, NDC, or clozapine against
inflammation-elicited damage of DA neurons were deter-
mined by quantifying functional changes of [3H]DA up-
take capacity and counts of THir neurons.
Cell lines
The rat microglia HAPI cell line was a gift from Dr. J. R.
Connor (Pennsylvania State University, Hershey, PA)
[33] and maintained as described previously [34]. Briefly,
HAPI cell line were maintained at 37 °C in DMEM
(Sigma) supplemented with 10 % fetal bovine serum,
50 U/ml penicillin, and 50 μg/ml streptomycin in a
humidified incubator with 5 % CO2 and 95 % air. The
cells were split or harvested every 3−5 days.
[3H]DA uptake assay
[3H]DA uptake assays were performed as described
previously [35]. Briefly, cells were incubated for 21 min
at 37 °C with 1 μM [3H]DA (PerkinElmer Life Sciences)
in Krebs-Ringer buffer. Cells were washed with ice-cold
Krebs-Ringer buffer three times and then were collected
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in 1 N NaOH. Radioactivity was determined by liquid
scintillation counting. Nonspecific DA uptake observed
in the presence of mazindol (10 μM) was subtracted.
NO and TNF-α assays
The production of nitric oxide (NO) was determined by
measuring accumulated levels of nitrite in the supernatant
with Griess reagent, and the release of tumor necrosis
factor-α (TNF-α) was measured with a TNF-α ELISA kit
from R&D Systems (Minneapolis, MN) following manu-
facture’s protocol.
Measurement of superoxide
The production of superoxide was assessed by measuring
the SOD-inhibitable reduction of the tetrazolium salt
WST-1 [36]. Briefly, primary neuron-glia cultures were
washed twice with HBSS balanced salt solution and then
pretreated with indicated concentrations of clozapine
metabolites dissolved in HBSS for 15 min. Immediately
after the addition of LPS, 50 μl of HBSS with or without
SOD (50 U/ml) was added to each well along with 50 μl of
WST-1 (1 mM) in HBSS. The absorbance at 450 nm was
read with a SpectraMax Plus microplate spectrophotom-
eter (Molecular Devices Sunnyvale). The amount of SOD-
inhibitable superoxide was calculated and expressed as
percentage of vehicle-treated control cultures.
Cell extracts
Whole cell lyses from HAPI microglia were prepared
with lysis buffer (Cell Signaling, Danvers, MA). Subcellu-
lar fractionation was performed as described previously
[37]. For subcellular fractions, HAPI microglia were
lysed in hypotonic lysis buffer (1 mM Tris, 1 mM KCl,
1 mM EGTA, 1 mM EDTA, 0.1 mM DTT, 1 mM PMSF,
and 10 μg/ml cocktail protease inhibitor) and then
subjected to Dounce homogenization (20–25 St, tight
pestle A). The lysates were centrifuged at 1600×g for
15 min; the supernatant was centrifuged at 100,000×g for
30 min. The pellets solubilized in 1 % nonidet P-40 hypo-
tonic lysis buffer were used as membranous fraction.
Western blot analysis
For western blot analysis, equal amounts of protein were
separated by 4−12 % Bis-Tris Nu-PAGE gel and trans-
ferred to polyvinylidenedifluoride membranes. The mem-
branes were blocked with 5 % nonfat milk and incubated
with rabbit antibodies (1:1000) against Iba-1, p47phox,
gp91phox (BD Transduction Laboratories), GAPDH, or rat
CD11b antibody overnight at 4 °C. The next day, mem-
branes were incubated with HRP-linked secondary anti-
rabbit or rat IgG (1:3000) for 2 h at room temperature.
ECL reagents (Amersham Biosciences) were used as a
detection system.
Statistical analysis
All group data are expressed as mean ± standard error of
mean (SEM). Group means were compared using one-
way analysis of variance (ANOVA) with treatment as the
independent variable. When ANOVA showed a significant
difference, pairwise comparisons between group means
were examined by Dunnett’s post hoc test. Differences
were considered significant at p value <0.05. Statistical
analysis was performed using GraphPad Prism version
6.00 for Windows.
Results
CNO and NDC protect DA neurons from LPS-induced
neurotoxicity
To investigate whether clozapine metabolites CNO
and NDC display neuroprotective effects, we used
inflammation-elicited neurotoxicity in vitro model by
treating neuron-glia cultures with Escherichia coli
endotoxin LPS. Both dopamine uptake capacity and
cell counts of THir neurons were performed to deter-
mine the function and survival of DA neurons 7 days
after LPS treatment. Results showed that pretreatment
with CNO or NDC protected DA neurons against LPS-
induced reduction of uptake capacity in a bell-shaped
curve (Fig. 1a, b). Similar patterns of dopaminergic neuro-
protection by both metabolites were observed in cell
number counts and morphological observation of neurites
of THir neurons (Fig. 1c–e). CNO and NDC were most
effective at the concentration of 0.01 and 0.1 μM, respect-
ively, in restoring DA uptake capacity (from 47.4 % of LPS
alone back to 79.9 and 77.1 % by CNO and NDC, respect-
ively) and ameliorating loss of THir neurons (from 57.5 %
of LPS alone back to 85.2 and 84.2 % by CNO and NDC,
respectively, Fig. 1a–e). However, higher concentrations of
two compounds showed lower protective efficacy. It is
unlikely due to their direct toxicity on neurons, since both
NDC and CNO alone at these doses caused no reduction
in either DA uptake function or THir cell number
(Fig. 1a–d). Thus, for the rest of studies, the most effective
concentrations of CNO (0.01 μM) and NDC (0.1 μM)
were used.
To compare the neuroprotective potency of clozapine
and its two metabolites, we performed DA uptake assay
using the most effective concentrations of each com-
pound: clozapine (1 μM) [25], NDC (0.1 μM), and CNO
(0.01 μM). The results showed that NDC and CNO in
these concentrations exerted equivalent neuroprotection
as clozapine (Fig. 1f ).
Microglia are essential in CNO- and NDC-elicited
neuroprotection
To investigate cellular and molecular mechanisms under-
lying the neuroprotective effects of CNO and NDC, we
first determined whether microglia were required. In this
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study, we compared the neurotoxic effect of 1-methyl-4-
phenylpyridinium (MPP+, the active metabolite of MPTP)
in neuron-glia culture with and without microglia (micro-
glia-depleted neuron-astrocyte culture). The reason we
used MPP+, instead of LPS, was because LPS failed to
produce dopamine neuron toxicity in microglia-depleted
cultures [38, 39]. In this model, DA neurotoxicity caused
by both direct MPP+ insult on neurons and reactive
microglial activation in response to MPP+-induced neur-
onal damage [39, 40]. CNO or NDC was shown to afford
their neuroprotective effects in neuron-glia culture, but not
in microglia-depleted neuron-astrocyte culture from MPP
+-mediated neurotoxicity (Fig. 2). The partial neuroprotec-
tive effect of CNO and NDC in MPP+-elicited neuron-glia
cultures was not observed in microglia-depleted cultures.
This result indicated that the presence of microglia in the
cultures is essential to show the neuroprotection of CNO
and NDC in MPP+-treated neuron-glia cultures. The sub-
sequent studies (Figs. 3 and 4) further demonstrated that
inhibition of microglial activation and release of proinflam-
matory immune factors is crucial to the anti-inflammatory
and neuroprotective effect of CNO and NDC.
CNO and NDC inhibit LPS-induced microglial activation
We have further investigated whether CNO and NDC
inhibit LPS-induced microglial activation. First, we ex-
amined the morphology changes of activated microglia
by immunostaining of Iba-1, a specific microglial marker
whose expression will be up-regulated during microglial
activation [41]. Results showed that LPS stimulation
resulted in increased cell number and size of Iba-1-
positive microglia and CNO or NDC pretreatment
Fig. 1 Potent effects of CNO and NDC in protecting DA neurons against LPS-induced neurotoxicity. Rat mesencephalic neuron-glia cultures were
pretreated with vehicle or indicated concentrations of CNO, NDC, or clozapine for 30 min before the addition of LPS (15 ng/ml). Seven days after LPS
treatment, the protective effects of CNO, NDC, or clozapine against inflammation-elicited damage of DA neurons were determined by quantifying
functional changes of [3H]DA uptake capacity (a, b, and f) and counts of THir neurons (c, d). E Representative images of anti-TH immunostaining in
cultures were shown. Results are expressed as the mean ± SEM or as a percentage of vehicle controls (mean ± SEM) from five independent
experiments performed in triplicate. **p < 0.01, #p < 0.05, ##p < 0.01. Scale bar = 50 μm
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mitigated these changes (Fig. 3a). CNO and NDC treat-
ment alone had no effect on microglial morphology.
Western blot analysis of Iba1 and CD11b (the α-chain of
β2-integrin receptor, another marker for activated
microglia [42]) was then performed to provide the quan-
titative estimation of microglial activation. Pretreatment
of CNO or NDC effectively inhibited the increased ex-
pression of Iba-1 and CD11b induced by LPS treatment
(Fig. 3b). To exclude the decreases of expression levels
of Iba-1 and CD11b which are due to the result of cell
toxicity of clozapine metabolites, we further investigated
whether CNO and NDC can affect microglial survival in
cultures prepared from Cx3CR1GFP/+, heterozygous
mice, which showed green fluorescence in microglia.
Our results showed that CNO and NDC alone or even
in combination with LPS had no effect on GFP-positive
microglia cell number in neuron-glia cultures up to
7 days after treatment (Additional file 1: Figure S1).
LPS-induced microglial activation (M1 phenotype) is
associated with the release of proinflammatory factors.
The release of the proinflammatory factors at their peak
release times, including superoxide (15 min), TNF-α
(3 h), and nitric oxide (NO, 24 h) [43–45], were subse-
quently detected in culture supernatants to assess the
role of CNO and NDC on LPS-induced microglial
activation. First, we showed that pretreatment with
CNO or NDC reduced the release of extracellular super-
oxide in LPS-challenged neuron-glia cultures (Fig. 4a, b).
Similar inhibitory effects of these two metabolites, but
less potent, were observed for the release of TNF-α and
NO (Fig. 4c–f ). It is interesting to note that CNO- and
NDC-elicited suppression of NO, TNF-α, and super-
oxide displayed a similar pattern, i.e., a bell-shaped dose
response curve; the most effective inhibitory doses were
0.01 and 0.1 μM for CNO and NDC, respectively, which
was identical to those in DA neuroprotection (Fig. 1).
These results suggest that CNO and NDC may modulate
inflammation-driven dopaminergic neurodegeneration by
inhibiting microglial activation and subsequent release of
these proinflammatory factors.
Microglial NOX2 is essential in mediating the
anti-inflammatory and neuroprotective effects of CNO
and NDC
Among the proinflammatory factors triggered by LPS,
release of superoxide was the most severely inhibited by
both CNO and NDC. Previous reports from our labora-
tory indicated that NOX2 is the major enzyme in micro-
glia that produces extracellular superoxide anions and is
a major contributor to the increase of the intracellular
reactive oxygen species (ROS), which in turn enhances
TNF-α production [46]. We further studied the role of
microglial NOX2, the key superoxide-producing enzyme
in mediating the neuroprotective effects of clozapine. For
this purpose, cell cultures prepared from mutant mice
deficient in gp91phox, the catalytic subunit of NOX2, and
from wild-type (gp91phox+/+) mice were used. Because
dopaminergic neurons cultured from gp91phox−/− mice are
more resistant than that from gp91phox+/+ mice to LPS-
induced neurotoxicity [47, 48], different concentrations of
LPS were used for both types of cultures in order to
produce equivalent loss of dopaminergic neurons: 50 ng/
ml for gp91phox−/− culture and 20 ng/ml for gp91phox+/+
culture. The results showed that pretreatment with CNO
or NDC significantly attenuated LPS-induced TNF-α
release and decreased DA uptake capacity in gp91phox+/+
cultures (Fig. 5a, c). In contrast, in gp91phox−/− culture,
CNO and NDC failed to show any effect on LPS-induced
production of TNF-α and reduction of [3H]DA uptake
capacity (Fig. 5b, d). These results suggest that NOX2
plays an indispensable role in CNO and NDC-afforded
neuroprotection.
Fig. 2 Microglia are required for the neuroprotective effects of CNO and NDC. a Rat mesencephalic neuron-glia culture containing 40 % neurons,
50 % astroglia, and 10 % microglia. b Microglia-depleted neuron-astrocyte culture containing neurons (~45 %), astroglia (~55 %), and less than
0.01 % microglia were treated with CNO (0.01 μM), NDC (0.1 μM), or vehicle for 30 min prior to the addition of MPP+ (0.25 μM). Seven days later,
[3H]DA uptake assays were performed. Results are expressed as a percentage of the vehicle controls (mean ± SEM) from three independent
experiments performed in triplicate. **p < 0.01, ##p < 0.01. NS not significant
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To determine the mechanism of how CNO and NDC
inhibit NOX2 activation, we determined the inhibitory ef-
fects of CNO and NDC on membrane translocation of
cytosolic subunits of NOX2, an essential step for the
activation of NOX2, in HAPI microglia cells. Western blot
analysis showed that the levels of p47phox was decreased in
the cytosolic fraction but increased in membrane fractions
in LPS-stimulated HAPI microglia cells (Fig. 6), indicating
membrane translocation of p47phox. As shown in Fig. 6c,
the changes of p47phox in both cytosolic and membrane
fractions induced by LPS were suppressed by CNO or
NDC treatment. No significant change of p47phox levels
was observed in CNO or NDC alone-treated cells, com-
pared with vehicle control. Quantitative analysis sup-
ported our observation by restoring p47phox levels in both
cytosolic (from 70.62 % of LPS alone back to 95.65 and
89.01 % by CNO and NDC, respectively) and membrane
fractions (from 154.2 % of LPS alone back to 122.18 and
118.83 % by CNO and NDC, respectively, Fig. 6c). These
results suggest that CNO and NDC inhibited NOX2 acti-
vation in microglia by interfering with the membrane
translocation of NOX2 cytosolic subunits.
Fig. 3 CNO and NDC inhibit LPS-induced microglial activation in vitro. a Rats mesencephalic neuron-glia cultures were treated with CNO
(0.01 μM), NDC (0.1 μM), or vehicle for 30 min prior to LPS (15 ng/ml) stimulation. Cultures were fixed at 7 days after treatments. Activation of
microglia was visualized by immunostaining with anti-Iba-1 antibody and the representative images were shown. b The inhibitory effects of CNO
and NDC on LPS-induced microglial activation were quantified by assessing the expressions of Iba-1 and CD11b using Western blot. GAPDH was
used as loading control. Results are presented as the mean ± SEM from three independent experiments. *p < 0.05. Scale bar = 50 μm
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CNO attenuates MPTP-induced dopaminergic neuron
damage and motor deficits without showing granulocyte
toxicity
To further verify the neuroprotective effects of clozapine
metabolite in vivo, a MPTP mouse PD model was used.
Since CNO and NDC are equally potent in protecting
dopaminergic neurons against inflammation-induced
damage, we selected CNO only to compare the dopamin-
ergic neuroprotective effect with clozapine. One day prior
to MPTP injection, clozapine or CNO (1 mg/kg, s.c.) was
administered twice daily for 21 consecutive days. The
protective effects of clozapine and CNO against MPTP-
induced motor deficits in mice were measured using
accelerating rotarod test at 14 days after initial MPTP
injection (Fig. 7a). Consistent with our previous report
[49], MPTP injection reduced the rotarod activity in mice
by about 43 % of latency time on the accelerating rod.
Both CNO and clozapine treatment significantly amelio-
rated MPTP-induced deficits of rotarod activity with
equal-potency (Fig. 7b). In addition to ameliorating motor
deficits, CNO and clozapine treatment displayed potent
efficacy in attenuating MPTP-induced dopaminergic
neurodegeneration (Fig. 7c). MPTP treatment caused
50 % loss of THir neurons in the SNpc, which were
reduced to 28 % in mice pretreated with CNO and
clozapine (Fig. 7c, d).
To detect the neutropenia of both clozapine and CNO,
the number of WBC in whole blood samples prepared
Fig. 4 CNO and NDC inhibit LPS-induced release of proinflammatory factors. Rat primary mesencephalic neuron-glia cultures were pretreated
with NDC or CNO for 30 min before LPS stimulation. a, b The production of superoxide was measured by SOD-inhibitable reduction of WST-1.
c–f The levels of TNF-α (c, d) and NO (e, f) in the supernatant were measured 3 and 24 h after LPS treatment, respectively. Results are expressed
as the mean ± SEM or as a percentage of LPS group (mean ± SEM) from five independent experiments performed in triplicate. **p < 0.01,
#p < 0.05, ##p < 0.01
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from mice treated with CNO and clozapine. Interestingly,
unlike parent compound clozapine, CNO had no signifi-
cant toxicity on neutrophils even combined with MPTP
up to 21 consecutive days of treatment (Fig. 7e).
CNO attenuates MPTP-induced reactive microgliosis
To determine whether CNO-afforded dopaminergic neu-
roprotection was linked to inhibition of microglial activa-
tion in vivo, we stained nigral microglia with CD11b, an
alpha chain of the β2 integrin receptor, 8 days after MPTP
injection. In MPTP-treated mice, activated microglia
characterized by a hypertrophied morphology and intensi-
fied CD11b staining were observed throughout the nigral
reticulate area (Fig. 8a). Analysis of CD11b density sup-
ported these morphological observations. Compared with
the MPTP alone group, both clozapine and CNO treat-
ment markedly attenuated microglial activation, as shown
by a reduced density of CD11b staining (Fig. 8a, b).
Discussion
In this study, we demonstrated that CNO and NDC,
two major metabolites of clozapine, exert potent anti-
inflammatory and neuroprotective effects in MPTP-
and inflammation-generated dopaminergic neurotox-
icity. CNO displayed the same potent efficacy as clo-
zapine in protecting DA neurons in MPTP-mediated
PD mouse model. Further, in vitro studies revealed a
dose-related correlation of anti-inflammatory effect and
their potency in neuroprotection by both CNO and NDC.
Mechanistic studies indicated that inhibition of microglial
NOX2-generated superoxide is the major target for the
anti-inflammatory actions: a novel pharmacological prop-
erty shared by both clozapine and its two metabolites.
This study clearly demonstrates that CNO and NDC
exhibit potent central effects and may contribute to some
of the neuropsychopharmacological actions of clozapine.
Neuroinflammation mediated by microglia is known
to be accompanied by oxidative stress, a common patho-
genic pathway for neurodegenerative process and psychi-
atric syndromes [50, 51]. Either overproduction of
oxidants such as ROS, or deficiencies in antioxidant
defense, or some combination thereof, can perturb the
redox homeostasis, resulting in oxidative damage [52].
Though in the process of neuroinflammation, both micro-
glia and astrocytes play critical roles in counterbalancing
the neurotoxicity or neuroprotective effect to a variety of
cytotoxic insults [53]; results from this study and our
previous report provided a novel anti-inflammatory mech-
anism of actions of clozapine and its metabolites as we
found that microglia were essential for the neuroprotec-
tive effect of CNO or NDC (shown in Fig. 2, protective ef-
fect disappeared as microglia were depleted). Among the
proinflammatory factors released by activated microglia,
superoxide production was the most severely inhibited by
CNO and NDC. Superoxide is one of the prominent
factors released by activated microglia, and NOX2 has
Fig. 5 Gp91phox genetic ablation blocks the anti-inflammatory and neuroprotective effects of CNO and NDC. Neuron-glia cultures prepared from
wild-type (gp91phox+/+) and NOX2-deficient (gp9 phox−/−) mice were pretreated with vehicle or CNO (0.01 μM) or NDC (0.1 μM) for 30 min followed
by LPS (20 ng/ml for gp91phox+/+or 50 ng/ml for gp9phox−/−) stimulation. a, b The supernatant levels of TNF-α were detected 3 h after LPS treatment.
c, d The protective effects of CNO and NDC against LPS-induced dopaminergic damage were assessed by DA uptake assay 7 days after treatment.
Results are expressed as the mean ± SEM or as a percentage of vehicle controls (mean ± SEM) from three independent experiments performed in
triplicate. **p < 0.01, ##p < 0.01. NS not significant
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been identified as a major source [54]. In addition to
extracellular ROS, NOX2 also contributes to increase
intracellular ROS that is a crucial secondary messenger
for microglial signaling and proinflammatory properties
[46, 55]. We found that both CNO and NDC inhibited
NOX2-derived superoxide production. Moreover, the
anti-inflammatory and neuroprotective effects of CNO
and NDC were abolished once the gene of NOX2 was
ablated, suggesting that NOX2 is the action target of
CNO and NDC. Our results suggest that the inhibitory
effects of CNO and NDC are independent of neurotrans-
mitter receptors but directly through acting on NOX2.
This possibility is consistent with the report showing that
clozapine is able to bind to neutrophil NOX2 in vitro [56].
Binding experiments for CNO/NDC to microglial NOX2
should be guaranteed in our future studies.
Clozapine is an atypical antipsychotic medicine used to
treat schizophrenia in patients whose symptoms are not
controlled with standard antipsychotic treatment. Despite
intensive studies on various G protein-coupled receptors
(GPCR), such as monoaminergic receptors and muscar-
inic receptors [11, 12], mechanisms underlying the anti-
psychotic action of clozapine remain unclear. Recent
advance in the research of neuroinflammation has pro-
vided a new avenue to uncover mechanisms underlying
the pathogenesis of neurodegenerative diseases and men-
tal disorders [57, 58]. There has been an increasing recog-
nition of the pathogenic role of microglia-mediated
neuroinflammation in psychiatric diseases such as depres-
sion, bipolar, schizophrenia, and obsessive-compulsive
disorder [22–24]. For instance, both postmortem and PET
studies have provided evidence for the existence of micro-
glial activation in the brains of schizophrenia patients
[59–61]. Some clinical trial studies have demonstrated a
beneficial effect of adjunctive minocycline, a well-known
anti-inflammatory compound, on the negative symptoms
of schizophrenia [62, 63] and on cognitive function [63].
Indeed, a wide variety of psychoactive drugs, such as anti-
depressants and antipsychotics, have been shown to sup-
press microglial activation [23, 47, 64, 65].
Fig. 6 CNO and NDC inhibit NOX2 activation. a HAPI microglia cells were pretreated with CNO (0.01 μM)/NDC (0.1 μM) for 30 min followed by
LPS stimulation. Fifteen minutes later, cells were harvested. The levels of p47phox were determined in both membrane and cytosolic fractions
using Western blot. GAPDH and gp91phox were used for internal controls of cytosolic and membrane fractions, respectively. b The band density
of blots were quantified. Results are expressed as a percentage of PMA group or vehicle controls (mean ± SEM) from three independent
experiments performed in triplicate. **p < 0.01, #p < 0.05, ##p < 0.01
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Earlier report from our laboratory illustrating the anti-
inflammatory and neuroprotective action of clozapine
lends further support to the notion that neuroinflamma-
tion may play a role in schizophrenia [25]. Current study
further extends our previous report indicating that CNO
and NDC, which are not shown to be centrally active
metabolites, possess both anti-inflammatory and neuro-
protective actions with equal or even higher potency than
that of clozapine. These findings raise a possibility that
these two metabolites may be used as anti-inflammatory
and neuroprotective agents for treating neurodegenerative
diseases or even as adjunctive drugs for treatment of
various mental diseases. Given that a relatively high risk of
neutropenia or agranulocytosis greatly hampers the long-
term usage of clozapine, if future studies find CNO or
NDC effective clinically in treating certain CNS diseases,
these two metabolites would possess a great advantage
over clozapine in terms of potential toxicities. It has been
Fig. 7 CNO and clozapine are equipotent in attenuating MPTP-induced dopaminergic neuron damage and motor deficits but show differential
effects on blood WBC counts. a Experimental designs. Eight-week-old male C57BL/6J mice received daily MPTP injections (20 mg/kg, s.c.) for six
consecutive days. From 1 day prior to MPTP injection, clozapine or CNO (1 mg/kg, s.c.) was administered twice daily for 21 consecutive days.
b Fourteen days after initial MPTP injection, the protective effects of clozapine and CNO against MPTP-induced motor deficits were measured
by the rotarod test. c Twenty-one days after the first injection of MPTP, dopaminergic neurons in the SNpc were immunostained with anti-TH
antibody and the numbers of THir cells in SNpc were counted. d The representative images of TH staining in the SN were shown. e Blood WBC
counts were shown in clozapine- and CNO-treated mice. Results are expressed as the mean ± SEM or as a percentage of vehicle controls (mean
± SEM). **p < 0.01, #p < 0.05, ##p < 0.01; n = 4–8. Scale bar = 100 μm
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reported that NDC is much less toxic to neutrophils in
comparison to clozapine and CNO shows no toxicity at all
at concentrations up to 100 μM [8, 66]. For this reason,
exploring the potential therapeutic use of CNO may be of
great interest for two reasons: (1) CNO shows higher
potency in both anti-inflammatory and neuroprotective
effects than that of NDC and clozapine in LPS-treated
neuron-glial cultures; (2) Consistent with previous re-
ported in vitro study, our study showed that CNO had no
significant toxicity on neutrophils in vivo even combined
with MPTP for up to 21 consecutive days of treatment.
Currently, testing the antipsychotic efficacy of CNO using
schizophrenia animal models is underway in our labora-
tory to determine the possibility that CNO can be effective
as a substitute of clozapine in treating this mental disease.
On the other hand, currently, the role of astrocyte in PD
remains controversial. We recently demonstrated that in
LPS-treated neuron-glia cultures, astrocytes tend to
protect DA neurons against neuroinflammation-mediated
degeneration through secretion of neurotrophic factor
GDNF [53]. We further revealed that astroglia may not
possess the capability to directly response to the innate
immune stimuli LPS, but rather depend on crosstalk with
microglia. However, the protective effects of astrocyte
against MPP+-induced DA degeneration in vitro were not
observed in our previous study, although the reason still
remains unclear [67]. Saijo et al. [68] reported that astro-
cyte is not only non-neuroprotective, but even amplified
the proinflammatory response in microglia, resulting in
exacerbated DA degeneration. Despite of these conflicting
results, targeting astrocyte, such as cystine/glutamate
exchange transporter [69], glutathione synthesis, [70] and
5-HT(1A) receptor [71], exhibited potent neuroprotective
effects in multiple models of PD. Therefore, future studies
focusing on the role astrocyte in the neuroprotective
effects elicited by CNO and NDC should be guaranteed,
which may provide new opportunities for developing
novel strategy for PD therapy.
Conclusions
In summary, our study shows that NDC and CNO, two
major metabolites of clozapine, share the same anti-
inflammatory and neuroprotective effect with their parent
drug. This study suggests that metabolites of clozapine
may also contribute to the therapeutic effect of the drug
in the treatment of schizophrenia with the mechanism
independent of neurotransmitter receptors. It also war-
rants animal study to investigate the in vivo metabolism
and antipsychotic effect of NDC and CNO to evaluate the
potential of NDC and CNO as substitute drugs for clinical
use as they are less toxic to neutrophils.
Additional file
Additional file 1: Figure S1. CNO and NDC had no effect on the
number of microglia. Mesencephalic neuron-glia cultures were prepared
from Cx3cr1gfp/+, heterozygous mice. Cultures were pretreated with
vehicle or indicated concentrations of CNO or NDC for 30 min before the
addition of LPS (15 ng/ml). After 7 days of treatment, no significant
difference of the number of microglia (green) in each group was
detected. Representative images of microglia at 7 days after treatment
in each group were shown. Scale bar = 50 μm. (DOC 180 kb)
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